Literature DB >> 26400875

Fallacies of last observation carried forward analyses.

John M Lachin1.   

Abstract

BACKGROUND: Last observation carried forward is a common statistical approach to the analysis of longitudinal repeated measures data where some follow-up observations may be missing. In a last observation carried forward analysis, a missing follow-up visit value is replaced by (imputed as) that subject's previously observed value, that is, the last observation is carried forward. The combination of the observed and imputed data is then analyzed as though there were no missing data.
PURPOSE: There have been numerous statistical demonstrations of faults of this approach. In 2012, the National Research Council's Panel on Handling Missing Data in Clinical Trials issued a report that raised concerns with the use of last observation carried forward and described alternative methods that offer greater statistical validity. Nevertheless, the method persists, and its use is rampant. A search of the key word "last observation carried forward" using Google Scholar yielded "about 2480" published citations during 2014 alone, the overwhelming majority presenting the results of scientific studies. However, there has not been a simple explanation of the statistical deficiencies of last observation carried forward. Such a description is presented herein.
RESULTS: A simple repeated measures model is described for quantitative observations at two times (e.g. 1 and 2 years), with complete values at 1 year that are used to impute by last observation carried forward the missing values at 2 years under the missing completely at random assumption. This results in a mixture distribution of observed and imputed values at 2 years with mean and variance that are a function of the mixture of the 1- and 2-year distributions. The expressions show that last observation carried forward is only unbiased when the distribution of the observed values at 1 year is exactly equal to the distribution of the missing values at 2 years, the latter, of course, being unknown. LIMITATIONS: When the values at 2 years are not randomly missing, no simple expressions for the mean and variance of the mixture distribution are possible without additional unverifiable assumptions.
CONCLUSION: All analyses using last observation carried forward are of questionable veracity, if not being outright specious (definition: appearing to be true but actually false). It is hoped that future studies will make a more vigorous attempt to minimize the amount of missing data and that more valid statistical analyses will be employed in cases where missing data occur. Last observation carried forward should not be employed in any analyses.
© The Author(s) 2015.

Entities:  

Keywords:  Last observation carried forward; imputation; missing data

Mesh:

Year:  2015        PMID: 26400875      PMCID: PMC4785044          DOI: 10.1177/1740774515602688

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  7 in total

1.  The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.

Authors:  R T O'Neill; R Temple
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

2.  Statistical considerations in the intent-to-treat principle.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  2000-06

3.  A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts.

Authors:  O Siddiqui; M W Ali
Journal:  J Biopharm Stat       Date:  1998-11       Impact factor: 1.051

4.  Last observation carried forward: a crystal ball?

Authors:  Michael G Kenward; Geert Molenberghs
Journal:  J Biopharm Stat       Date:  2009-09       Impact factor: 1.051

5.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

6.  The prevention and treatment of missing data in clinical trials.

Authors:  Roderick J Little; Ralph D'Agostino; Michael L Cohen; Kay Dickersin; Scott S Emerson; John T Farrar; Constantine Frangakis; Joseph W Hogan; Geert Molenberghs; Susan A Murphy; James D Neaton; Andrea Rotnitzky; Daniel Scharfstein; Weichung J Shih; Jay P Siegel; Hal Stern
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

7.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

  7 in total
  46 in total

1.  Assessing the longitudinal stability of latent classes of substance use among gay, bisexual, and other men who have sex with men.

Authors:  Kiffer G Card; Heather L Armstrong; Allison Carter; Zishan Cui; Lu Wang; Julia Zhu; Nathan J Lachowsky; David M Moore; Robert S Hogg; Eric A Roth
Journal:  Drug Alcohol Depend       Date:  2018-05-22       Impact factor: 4.492

Review 2.  Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD.

Authors:  Haochang Shou; Jesse Y Hsu; Dawei Xie; Wei Yang; Jason Roy; Amanda H Anderson; J Richard Landis; Harold I Feldman; Afshin Parsa; Christopher Jepson
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-27       Impact factor: 8.237

3.  Clinical and Metabolic Response to Vitamin D Supplementation in Endometrial Hyperplasia: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Zohreh Tabassi; Sedigheh Bagheri; Mansooreh Samimi; Hamid Reza Gilasi; Fereshteh Bahmani; Maryam Chamani; Zatollah Asemi
Journal:  Horm Cancer       Date:  2017-03-10       Impact factor: 3.869

4.  Vitamin D and Evening Primrose Oil Administration Improve Glycemia and Lipid Profiles in Women with Gestational Diabetes.

Authors:  Mehri Jamilian; Maryam Karamali; Mohsen Taghizadeh; Nasrin Sharifi; Zahra Jafari; Mohammad Reza Memarzadeh; Mahnaz Mahlouji; Zatolla Asemi
Journal:  Lipids       Date:  2016-01-19       Impact factor: 1.880

5.  Exercise and Academic Performance Among Children With Attention-Deficit Hyperactivity Disorder and Disruptive Behavior Disorders: A Randomized Controlled Trial.

Authors:  Jared D Ramer; María E Santiago-Rodríguez; Catherine L Davis; David X Marquez; Stacy L Frazier; Eduardo E Bustamante
Journal:  Pediatr Exerc Sci       Date:  2020-05-25       Impact factor: 2.333

6.  The Effects of the Nurse Navigation Program in Promoting Colorectal Cancer Screening Behaviors: a Randomized Controlled Trial.

Authors:  Elif Temucin; Nursen O Nahcivan
Journal:  J Cancer Educ       Date:  2020-02       Impact factor: 2.037

7.  Comparison of modified Bass, Fones and normal tooth brushing technique for the efficacy of plaque control in young adults- A randomized clinical trial.

Authors:  Chandrashekar Janakiram; Naveen Varghese; Ramanarayanan Venkitachalam; Joe Joseph; Karuveettil Vineetha
Journal:  J Clin Exp Dent       Date:  2020-02-01

Review 8.  Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Kim Boesen; Asger Sand Paludan-Müller; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24

9.  Outcome following surgical stabilization of distal diaphyseal and supracondylar femoral fractures in dogs.

Authors:  Francisco Silveira; Isobel C Monotti; Anna M Cronin; Nick J Macdonald; Scott Rutherford; Kornelia Tiffinger; Ian Faux; Javier Rincon-Alvarez; Elvin Kulendra; Francesca Tavola; Bruno Santos; Neil J Burton
Journal:  Can Vet J       Date:  2020-10       Impact factor: 1.008

10.  Randomized Controlled Trial of Exercise for ADHD and Disruptive Behavior Disorders.

Authors:  Eduardo Esteban Bustamante; Catherine Lucy Davis; Stacy Lynn Frazier; Dana Rusch; Louis F Fogg; Marc S Atkins; David Xavier Marquez
Journal:  Med Sci Sports Exerc       Date:  2016-07       Impact factor: 5.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.